
AUSTRALIAN PRODUCT INFORMATION

SUDAFED® Sinus + Pain Relief Day & Night Tablets (Paracetamol, Pseudoephedrine hydrochloride, Triprolidine hydrochloride)

1 Name of the Medicine

Paracetamol

Pseudoephedrine Hydrochloride

Triprolidine Hydrochloride

2 Qualitative and Quantitative composition

SUDAFED® Sinus + Pain Relief Day & Night tablets contain two separate formulations: day tablets and night tablets.

Each SUDAFED® Sinus + Pain Relief Day & Night **day** tablet contains pseudoephedrine hydrochloride 30 mg, paracetamol 500 mg

For the full list of excipients, see Section 6.1 List of excipients.

Each SUDAFED® Sinus + Pain Relief Day & Night **night** tablet contains pseudoephedrine hydrochloride 30 mg, paracetamol 500 mg, triprolidine hydrochloride 1.25 mg

For the full list of excipients, see Section 6.1 List of excipients.

3 Pharmaceutical form

SUDAFED® Sinus + Pain Relief Day & Night day tablets are white, round, flat and uncoated with wide bevelled edges. They are scored and coded 'P3F' on one face, and the other face is plain.

SUDAFED® Sinus + Pain Relief Day & Night night tablets are turquoise, bevelled, capsule-shaped, flat and uncoated. They are scored on one face and coded 'S3F' each side of the score, and plain on the other face.

4 Clinical Particulars

4.1 Therapeutic Indications

SUDAFED® Sinus + Pain Relief Day & Night provides fast and effective relief from sinus pain and congestion day and night.

4.2 Dose and Method of Administration

The recommended dosage of SUDAFED® Sinus + Pain Relief Day & Night for adults and children 12 years and over is:

- Day – take 2 day tablets in the morning and 2 tablets in the afternoon.
- Night – take 2 night tablets in the evening at bedtime.

SUDAFED® Sinus + Pain Relief Day & Night should not be taken by children under 12 years of age without medical advice.

Use in adults

Paracetamol should not be taken for more than a few days at a time except on medical advice.

Use in children

Paracetamol should not be taken for more than 48 hours except on medical advice.

4.3 Contraindications

Pseudoephedrine is contraindicated for use in patients:

- with known hypersensitivity or idiosyncratic reaction to pseudoephedrine (or any of the other ingredients in the product)
- with severe or uncontrolled hypertension or severe coronary artery disease
- taking monoamine oxidase inhibitors (MAOIs) or who have taken MAOIs within the previous 14 days
- with severe acute or chronic kidney disease/renal failure.

Paracetamol is contraindicated for use in patients with known hypersensitivity or idiosyncratic reaction to paracetamol (or any of the other ingredients in the product).

Triprolidine is contraindicated for use in patients with:

- a history of hypersensitivity to the substance or substances of similar chemical structure (or any of the other ingredients in the product)
- narrow-angle glaucoma
- stenosing peptic ulcer
- symptomatic prostatic hypertrophy
- bladder neck obstruction
- pyloroduodenal obstruction.

Triprolidine is contraindicated for use in:

- newborns or premature infants
- lactating women
- patients taking monoamine oxidase inhibitors (MAOIs).

Refer to '4.5 Interactions with other medicines and other forms of interactions' for additional information.

4.4 Special Warnings and Precautions for Use

High Anion Gap Metabolic Acidosis

Cases of high anion gap metabolic acidosis (HAGMA) due to pyroglutamic acidosis have been reported in patients with severe illness such as severe renal impairment and sepsis, or patients with malnutrition and other sources of glutathione deficiency (e.g. chronic alcoholism) who were treated with paracetamol at therapeutic dose for a prolonged period or a combination of paracetamol and flucloxacillin. If HAGMA due to pyroglutamic acidosis is suspected, prompt discontinuation of paracetamol and close monitoring is recommended. The measurement of urinary 5-oxoproline may be useful to identify pyroglutamic acidosis as underlying cause of HAGMA in patients with multiple risk factors.

Posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS)

Cases of PRES and RCVS have been reported with the use of pseudoephedrine-containing products (see section 4.8). The risk is increased in patients with severe or uncontrolled hypertension, or with severe acute or chronic kidney disease/renal failure (see section 4.3).

Pseudoephedrine should be discontinued and immediate medical assistance sought if the following symptoms occur: sudden severe headache or thunderclap headache, nausea, vomiting, confusion, seizures and/or visual disturbances. Most reported cases of PRES and RCVS resolved following discontinuation and appropriate treatment.

Pseudoephedrine should be used with caution in patients with:

- hypertension
- hyperthyroidism or thyroid disease
- diabetes mellitus
- coronary heart disease
- ischaemic heart disease
- glaucoma
- prostatic hypertrophy
- severe hepatic dysfunction.

Some cases of ischaemic colitis have been reported with pseudoephedrine. Pseudoephedrine should be discontinued and medical advice sought if sudden abdominal pain, rectal bleeding or other symptoms of ischaemic colitis develop.

If signs and symptoms such as formation of small pustules occur, with or without pyrexia or erythema, then treatment with pseudoephedrine should be discontinued and a physician should be consulted.

Serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens - Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported very rarely in patients receiving paracetamol. Patients should be informed about the signs of serious skin reactions and use of the drug should be discontinued at the first

appearance of skin rash or any other sign of hypersensitivity.

Paracetamol should be used with caution in patients with:

- impaired hepatic function
- impaired renal function
- chronic alcoholism

Triprolidine may cause drowsiness and may increase the effects of alcohol. Drowsiness may continue the following day. Those affected should not drive or operate machinery; alcohol should be avoided.

Use with caution in patients with renal or hepatic impairment and in patients with epilepsy, and in patients with respiratory conditions such as emphysema, chronic bronchitis, or acute or chronic bronchial asthma.

Refer to '4.5 Interactions with other medicines and other forms of interactions' for additional information.

Use in hepatic impairment

Use with caution in patients with hepatic impairment or severe hepatic dysfunction.

Use in renal impairment

Use with caution in patients with renal impairment or renal dysfunction.

Pseudoephedrine is contraindicated for use in patients with severe acute or chronic kidney disease/renal failure (see section 4.3 Contraindications)

Use in elderly

The elderly may experience paradoxical excitation with triprolidine. The elderly are more likely to have CNS depressive side effects, including confusion.

Paediatric use

Children may experience paradoxical excitation with triprolidine.

Effects on laboratory tests

No data available.

4.5 Interactions with other medicines and other forms of interactions

The following interactions with pseudoephedrine have been noted:

- antidepressant medication eg tricyclic antidepressants and monoamine oxidase inhibitors (MAOIs) – may cause a serious increase in blood pressure or hypertensive crisis
- other sympathomimetic agents, such as decongestants, appetite suppressants and amphetamine-like psychostimulants – may cause an increase in blood pressure and additive effects
- methyldopa and β -blockers – may cause an increase in blood pressure
- urinary acidifiers enhance elimination of pseudoephedrine
- urinary alkalinisers decrease elimination of pseudoephedrine.

The following interactions with paracetamol have been noted:

- anticoagulant drugs (warfarin) – dosage may require reduction if paracetamol and anticoagulants are taken for a prolonged period of time
- paracetamol absorption is increased by substances that increase gastric emptying, e.g. metoclopramide
- paracetamol absorption is decreased by substances that decrease gastric emptying, e.g. propantheline, antidepressants with anticholinergic properties, and narcotic analgesics
- paracetamol may increase chloramphenicol concentrations
- the risk of paracetamol toxicity may be increased in patients receiving other potentially hepatotoxic drugs or drugs that induce liver microsomal enzymes such as alcohol and anticonvulsant agents
- paracetamol excretion may be affected and plasma concentrations altered when given with probenecid
- colestyramine reduces the absorption of paracetamol if given within 1 hour of paracetamol

Caution should be taken when paracetamol is used concomitantly with flucloxacillin as concurrent intake has been associated with high anion gap metabolic acidosis due to pyroglutamic acidosis, especially in patients with risks factors (see section 4.4) The following interactions with triprolidine have been noted:

- CNS depressants (alcohol, sedatives, opioid analgesics, hypnotics) – may cause an increase in sedation effects
- monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) – may prolong and intensify the anticholinergic and CNS depressive effects.

4.6 Fertility, Pregnancy and Lactation

Effects on Fertility

No Data available.

Use in pregnancy

The pregnancy categorisation is B2. Pseudoephedrine has been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human foetus having been observed. Studies in animals are inadequate or may be lacking, but available data shows no evidence of an increased occurrence of foetal damage.

Pseudoephedrine should be used in pregnancy only if the potential benefits to the patient are weighed against the possible risk to the foetus.

Paracetamol has been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the foetus having been observed.

Triprolidine has been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the foetus having been observed.

Use in lactation

Pseudoephedrine is secreted in breast milk in small amounts. It has been estimated that 0.5% to 0.7% of a single dose of pseudoephedrine ingested by the mother will be excreted in the breast milk over 24 hours. Therefore it is not recommended for breastfeeding mothers unless the potential benefits to the patient are weighed against the possible risk to the infant.

Paracetamol is excreted in small amounts (< 0.2%) in breast milk. Maternal ingestion of paracetamol in usual analgesic doses does not appear to present a risk to the breastfed infant.

Triprolidine is excreted in breast milk. Therefore it is not recommended for breastfeeding mothers unless the potential benefits to the patient are weighed against the possible risk to the infant.

4.7 Effects on the ability to drive and use machines

Triprolidine may cause drowsiness and may increase the effects of alcohol. Drowsiness may continue the following day. Those affected should not drive or operate machinery; alcohol should be avoided.

4.8 Adverse Effects (Undesirable Effects)

Adverse drug reactions identified during post-marketing experience are detailed in the table below. Additionally the following should be noted:

Adverse effects of pseudoephedrine include elevated blood pressure

Children and the elderly are more likely to experience adverse effects than other age groups.

Side effects of paracetamol are rare and usually mild, although haematological reactions have been reported. Overdosage with paracetamol if left untreated can result in severe, sometimes fatal liver damage and rarely, acute renal tubular necrosis.

CNS depressive effects of triprolidine include sedation and impaired performance (impaired driving performance, poor work performance, incoordination, reduced motor skills, and impaired information processing). Performance may be impaired in the absence of sedation and may persist the morning after a night-time dose.

CNS stimulatory effects of triprolidine may include appetite stimulation, muscle dyskinesias and activation of epileptogenic foci.

High doses of triprolidine may cause agitation, and irritability.

Side effects of triprolidine associated with cholinergic blockage include dryness of the eyes, mouth and nose, blurred vision, urinary hesitancy and retention, constipation and tachycardia.

Cases of high anion gap metabolic acidosis due to pyroglutamic acidosis have been observed in patients with risk factors using paracetamol (see section 4.4). Pyroglutamic acidosis may occur as a consequence of low glutathione levels in these patients.

Adverse drug reactions identified during post-marketing experience with paracetamol, pseudoephedrine, the combination of pseudoephedrine and triprolidine, the combination of pseudoephedrine and paracetamol or the combination paracetamol, pseudoephedrine and triprolidine appear in the following table. The frequency category was estimated from spontaneous reporting rates according to the following convention:

Very common	≥1/10
Common	≥1/100 and < 1/10
Uncommon	≥1/1,000 and <1/100
Rare	≥1/10,000 and <1/1,000
Very rare	<1/10,000
Not known (cannot be estimated from the available data)	

Frequency category	Adverse Event Preferred Term
Immune System Disorders	
Very Rare	<i>Anaphylactic reaction</i>
Very Rare	<i>Hypersensitivity</i>
Psychiatric Disorders	
Very Rare	<i>Hallucination</i>
Very Rare	<i>Anxiety</i>
Very Rare	<i>Euphoric mood</i>
Very Rare	<i>Insomnia</i>
Very Rare	<i>Nervousness</i>
Very Rare	<i>Restlessness</i>
Very Rare	<i>Irritability</i>
Very Rare	<i>Hallucination visual</i>
Nervous System Disorders	
Very Rare	<i>Cerebrovascular accident*</i>
Very Rare	<i>Dizziness</i>
Very Rare	<i>Headache</i>
Very Rare	<i>Paraesthesia</i>
Very Rare	<i>Psychomotor hyperactivity (in the pediatric population)</i>
Very Rare	<i>Somnolence</i>
Very Rare	<i>Tremor</i>
Very Rare	<i>Posterior Reversible Encephalopathy Syndrome (PRES) (see section 4.4)</i>

Very Rare	<i>Reversible Cerebral Vasoconstriction Syndrome (RCVS) (see section 4.4)</i>
Common	<i>Impaired performance (impaired driving performance, poor work performance, incoordination, reduced motor skills, and impaired information processing)</i>
Common	<i>Sedation</i>
Not Known	<i>Activation of epileptogenic foci</i>

Cardiac Disorders

Very Rare	<i>Arrhythmia</i>
Very Rare	<i>Myocardial infarction*</i>
Very Rare	<i>Palpitations</i>
Very Rare	<i>Tachycardia</i>

Respiratory, Thoracic, and Mediastinal Disorders

Very Rare	<i>Epistaxis</i>
Common	<i>Dry nose</i>

Gastrointestinal Disorders

Very Rare	<i>Abdominal Discomfort</i>
Very Rare	<i>Colitis ischaemic</i>
Very Rare	<i>Dry mouth</i>
Very Rare	<i>Nausea</i>
Very Rare	<i>Diarrhoea</i>
Very Rare	<i>Vomiting</i>
Common	<i>Constipation</i>

Skin and Subcutaneous Tissue Disorders

Very Rare	<i>Pruritus</i>
Very Rare	<i>Angioedema</i>
Very Rare	<i>Pruritic rash</i>
Very Rare	<i>Rash</i>
Very Rare	<i>Urticaria</i>
Very Rare	<i>Acute generalised exanthematous pustulosis</i>
Very Rare	<i>Fixed eruption</i>

Renal and Urinary Disorders

Very Rare	<i>Dysuria</i>
Very Rare	<i>Urinary retention</i>
Common	<i>Urinary hesitancy</i>

General Disorders and Administration Site Conditions

Very Rare	<i>Fatigue</i>
-----------	----------------

Very Rare	<i>Feeling jittery</i>
Investigations	
Very Rare	<i>Blood pressure increased</i>
Very Rare	<i>Transaminases increased</i>
Blood and lymphatic disorders	
Rare	<i>Haematological reactions</i>
Musculoskeletal and connective tissue disorders	
Not known	<i>Muscle dyskinesias</i>
Metabolism and nutrition disorders	
Not known	<i>Appetite stimulation</i>
Eye disorders	
Not known	<i>Dry Eyes</i>
Not known	<i>Blurred vision</i>
Metabolism and nutrition disorders	
Not known	<i>High anion gap metabolic acidosis</i>

* These events have been reported very rarely in post-marketing safety. A recent postauthorisation safety study (PASS) did not provide any evidence of increased risk of myocardial infarction or cerebrovascular accident associated with the use of vasoconstrictors for nasal decongestion, including pseudoephedrine.

Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdosage

If an overdose is taken or suspected, immediately contact the Poisons Information Centre (in Australia, call 13 11 26; in New Zealand call 0800 764 766) for advice, or go to a hospital straight away even if you feel well because of the risk of delayed, serious liver damage.

Overdosage with paracetamol if left untreated can result in severe, sometimes fatal liver damage, and rarely, acute renal tubular necrosis.

5 Pharmacological Properties

5.1 Pharmacodynamics properties

Mechanism of action

Pseudoephedrine has direct and indirect sympathomimetic activity and is an effective decongestant in the upper respiratory tract. It is a stereoisomer of

ephedrine and has a similar action, but has been found to have less pressor activity and fewer central nervous system (CNS) effects.

Sympathomimetic agents are used as nasal decongestants to provide symptomatic relief. They act by causing vasoconstriction resulting in redistribution of local blood flow to reduce oedema of the nasal mucosa, thus improving ventilation, drainage and nasal stuffiness.

Paracetamol is a p-aminophenol derivative that exhibits analgesic and antipyretic activity. It does not possess anti-inflammatory activity. Paracetamol is thought to produce analgesia through a central inhibition of prostaglandin synthesis.

Triprolidine competes with histamine at central and peripheral histamine₁-receptor sites, preventing the histamine-receptor interaction and subsequent mediator release.

Triprolidine is a highly lipophilic molecule that readily crosses the blood-brain barrier. Triprolidine is highly selective for histamine₁-receptors but has little effect on histamine₂ or histamine₃ receptors. Triprolidine also activates 5-hydroxytryptamine (serotonin) and α -adrenergic receptors and blocks cholinergic receptors.

Clinical trials

No data available.

5.2 Pharmacokinetic Properties

Pseudoephedrine is readily absorbed from the gastrointestinal tract. It is largely excreted unchanged in the urine together with small amounts of its hepatic metabolite. It has a half-life of about 5-8 hours; elimination is enhanced and half-life reduced accordingly in acid urine. Small amounts are distributed into breast milk.

Paracetamol is readily absorbed from the gastrointestinal tract with peak plasma concentrations occurring about 10 to 60 minutes after oral administration.

Paracetamol is distributed into most body tissues. Plasma protein binding is negligible at usual therapeutic doses but increases with increasing doses. The elimination half-life varies from about 1 to 3 hours.

Paracetamol is metabolised extensively in the liver and excreted in the urine mainly as inactive glucuronide and sulfate conjugates. Less than 5% is excreted unchanged. The metabolites of paracetamol include a minor hydroxylated intermediate which has hepatotoxic activity. This intermediate metabolite is detoxified by conjugation with glutathione; however, it can accumulate following paracetamol overdosage (more than 150 mg/kg or 10 g total paracetamol ingested) and if left untreated can cause irreversible liver damage.

Paracetamol is metabolised differently by premature infants, newborns, infants and young children compared to adults, the sulfate conjugate being predominant.

After absorption from the gastro-intestinal tract, triprolidine hydrochloride is metabolised; a carboxylated derivative accounts for about half the dose excreted in

the urine. Reported half-lives vary from 3 to 5 hours or more. Triprolidine is distributed into breast milk.

5.3 Preclinical safety data

Genotoxicity

No data available.

Carcinogenicity

No data available.

6 Pharmaceutical Particulars

6.1 List of excipients

SUDAFED® Sinus + Pain Relief Day & Night tablets contain two separate formulations: day tablets and night tablets.

SUDAFED® Sinus + Pain Relief Day & Night **day** tablet contains the excipients: microcrystalline cellulose, hydroxypropylcellulose, magnesium stearate, sodium starch glycollate, pregelatinised wheat starch, stearic acid.

SUDAFED® Sinus + Pain Relief Day & Night **night** tablet contains the excipients: brilliant flue FCF, microcrystalline cellulose, hydroxypropylcellulose, magnesium stearate, povidone, quinoline yellow.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine. Refer to Section 4.5 – Interactions with other medicines and other forms of interactions.

6.3 Shelf Life

3 Years.

6.4 Special Precautions for storage

Store below 25°C. Keep dry. Protect from light.

6.5 Nature and Contents of container

SUDAFED® Sinus + Pain Relief Day & Night tablets are available in blister packs (PVC/PVDC) of the following sizes:

- 6 tablets (S3) Pharmacist Only Medicine
- 24 tablets[#] (S3) Pharmacist Only Medicine

marketed


6.6 Special Precautions for disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.


6.7 Physicochemical Properties

Chemical Structure


Paracetamol



Pseudoephedrine Hydrochloride



Triprolidine Hydrochloride



CAS number

Paracetamol

CAS Registry Number: 103-90-2

Pseudoephedrine Hydrochloride

CAS Registry Number: 345-78-8

Triprolidine Hydrochloride

CAS Registry Number: 6138-79-0

7 Medicine Schedule (Poisons Standard)

Schedule 3

8 Sponsor

Kenvue Pacific Australia
New Zealand
Sydney, NSW, Australia and Auckland
®Registered trademark

9 Date of First Approval

28 September 2006

10 Date of Revision

03 December 2025

Summary table of changes

Section Changed	Summary of new information
4.3	Additional contraindications added
4.4, 4.5, 4.8	Additional warning statements added
8	Update Sponsor details